BIIB 023

Drug Profile

BIIB 023

Alternative Names: Anti-TWEAK monoclonal antibody - Biogen; BIIB-023

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biogen Idec
  • Developer Biogen
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action TNFSF12 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Muscular atrophy
  • Discontinued Lupus nephritis; Rheumatoid arthritis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Muscle-wasting(In volunteers) in USA (IV, Infusion)
  • 26 Oct 2015 Discontinued - Phase-I for Rheumatoid arthritis in Russia, Ukraine, USA (IV)
  • 26 Oct 2015 Discontinued - Preclinical for Rheumatoid arthritis in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top